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Alone among herpesviruses, persistent Cytomegalovirus (CMV) markedly alters the numbers and proportions of
peripheral immune cells in infected-vs-uninfected people. Because the rate of CMV infection increases with age in most
countries, it has been suggested that it drives or at least exacerbates “immunosenescence”. This contention remains
controversial and was the primary subject of the Third International Workshop on CMV & Immunosenescence which
was held in Cordoba, Spain, 15-16th March, 2012. Discussions focused on several main themes including the effects of
CMV on adaptive immunity and immunosenescence, characterization of CMV-specific T cells, impact of CMV infection
and ageing on innate immunity, and finally, most important, the clinical implications of immunosenescence and CMV
infection. Here we summarize the major findings of this workshop.Introduction
The impact of cytomegalovirus on the immune system
and its relevance for the decline of immune function
with ageing was discussed by international experts dur-
ing the Third International Workshop on CMV &
Immunosenescence held in Cordoba, Spain, 15-16th
March, 2012 (local organizer, Prof. R. Solana). This
followed two previous Workshops held in Tubingen,
Germany in 2009, and Cambridge, UK in 2010, the out-
comes of which were summarized in this Journal by
Pawelec et al. [1] and Wills et al. [2]. This commentary
summarizes the major issues discussed at the Third
Workshop in this series with an emphasis on those
questions raised in the previous meetings that were left
open. The meeting ended with a session of perspectives
and closing remarks that included a discussion summary
and several action items (Figure 1), and will be followed* Correspondence: rsolana@uco.es
1Immunology Unit, Instituto Maimónides de Investigación Biomédica de
Córdoba (IMIBIC)-Reina Sofia University Hospital-University of Cordoba,
Cordoba, Spain
Full list of author information is available at the end of the article
© 2012 Solana et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orby a 4th Workshop to be organized by Prof. P. Sansoni
in Parma, Italy, 25-27th March, 2013.
Biomarkers of Immunosenescence and CMV infection
Pawelec (Tübingen, Germany) reviewed the recent
advances in immunosenescence defined as the deleteri-
ous age-associated changes to immunity observed in all
mammals studied so far. It was suggested that a better
designation might be immune frailty as a continuous
variable rather than a discrete state. The clinical impact
of the observed age-associated changes in components
of innate and adaptive immunity is mostly not clear in
humans, and controversial data exist regarding the
mechanisms of immunosenescence and the identifica-
tion of new markers. In longitudinal studies of Swedish
octogenarians and nonagenarians (OCTO and NONA)
an immune risk profile (IRP) was proposed that was
associated with increased mortality. The IRP was present
in approximately 15% of individuals at baseline and 4
year mortality was almost double in individuals with IRP
compared with non-IRP individuals. The main limita-
tions of the IRP were emphasized. Thus, it has beenLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 CMV and immunosenescence: Open questions. The relevance of the following questions on the role of CMV infection on
immunosenescence and inflamm-aging were highlighted: 1) the need to standardize the panel of mAbs used to asses lymphocyte subsets
alterations, 2) the role of each lymphoid subset in anti-CMV response, 3) the significance of CMV-induced inflammation and 4) the complexity of
CMV infection in humans.
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erly people in one particular country but we do not
know if these results can be extrapolated to larger and
younger samples in different countries. The initial IRP
analysis lacked the sophistication of modern immune
analysis and it is unknown at which age it may become
relevant and its association with underlying diseases is
unclear. In addition, the IRP does not take into account
many other clinical factors, such as nutritional status,
psychological stress or inflammatory status that may be
relevant, as discussed intensively during this workshop.
Recent reports have shown that signs of inflammation
such as increased CRP or IL-6 are independent of the
IRP and must be accounted for separately. In the Na-
tional Health and Examination Survey (NHANES) III
study, combined CMV-seropositivity and higher CRP
levels were associated with increased mortality. A rela-
tionship between functional ability in older people and
the immune system has been documented in several
studies: frail elderly individuals have higher CMV titers,
elevated IL-6 and lower responses to influenza vaccin-
ation, but the interrelations between these are not clear.
It is also not clear if CMV reactivates more often in the
elderly with or without frailty and if higher levels of anti-
bodies against CMV are associated with lower survival.
Studies of CMV prevalence in different populations have
shown high variability. In elderly Chinese Singaporeans,
CMV prevalence is very high (99%) as shown by Larbi(Singapore). Since 2003, the Singapore Longitudinal Age-
ing Study (SLAS) recruiting individuals over 55 years of
age has characterized over 4000 study participants for nu-
tritional, behavioural, metabolic, social, and biological
parameters. The extensive clinical information collected
over the years enables us to now identify immune para-
meters associated with chronic conditions (eg. diabetes,
hypertension, high cholesterol). A global approach includ-
ing immune monitoring and bioinformatics should enable
the identification of immune correlates of longevity and
co-morbidities, in a systems biology approach. Data pre-
sented highlighted that immunological history in Asian
elderly (eg. Dengue, H. pylori, CMV, EBV) is different
from in other parts of the world. This may be of major im-
portance for the identification of other or additional driv-
ing forces than CMV leading to immunosenescence.
CMV IgG levels are different in CMV-seropositive elderly
depending on the presence of co-morbidities (eg. diabetes)
suggesting that stratification of elderly individuals based
on any parameter related to chronic conditions should be
considered. Correlations between CMV IgG and inflam-
matory markers were presented and also shown to correl-
ate with the frequency of differentiated CD8+CD28-
CD27- T cells. The data presented suggest that better
stratification of the elderly should be performed in order
to understand the role CMV in healthy ageing and how
other conditions may synergize or conflict with CMV-
induced effects at the immunological level.
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on familial longevity as illustrated by the Leiden Longev-
ity study (LLS), which includes 450 families in which off-
spring enjoy a standardized mortality rate 30% lower
than their partners from the general population. Off-
spring from long-lived families had a significantly lower
number of late-stage, possibly terminally, differentiated
CD8+ T cells (CD45RA−CCR7−CD27−CD28−) and
latent CMV infection did not have the same impact
on the percentage of naive (CD45RA+CCR7+CD27+
CD28+) and late-differentiated effector memory CD8+
T-cells as it has in the rest of the population. Thus, the
decrease in naïve and accumulation of late-differentiated
“senescent” CD8+ T cells that is commonly taken as
a hallmark of immunosenescence was not seen in
these subjects. CMV-associated pro-inflammatory status
(assayed as CRP levels) in CMV-seropositive offspring
from long-lived families was also lower than in the gen-
eral population, but no differences in the cellular
responses to CMV in vitro were found. However, ana-
lysis of the serological response to CM2, a fusion protein
containing the C-terminal portion of viral protein
pUL44 and a highly reactive fragment of pUL57, asso-
ciated with active infection, revealed that the percentage
of individuals with detectable levels of IgM and IgG anti-
bodies to CM2 was lower in the offspring compared to
their partners; in parallel, a lower percentage of naïve
CD8+ cells and higher percentage of late-differentiated
CD8+ cells was seen in subjects with CM2-binding IgG
and IgM antibodies. No differences were found in naïve
CD4 cells. These data suggest either a lower reactiva-
tion rate of CMV in offspring predisposed for familial
longevity, or better immune control of the virus on
reactivation, and may help to explain the absence
of CMV-associated markers of immunosenescence in
these individuals [3].
The identification of phenotypes that could be used to
anticipate which individuals are at higher risk for immu-
nosenescence and mortality (“biomarkers”) remains elu-
sive. The analysis of 2 year survival in a cohort of
donors over 65 from the south of Spain (Sevilla, Spain)
confirmed that CD4/CD8 ratios below 1 as well as mar-
kers of inflammation (neutrophilia, high CRP levels,
IL-6) and thymic function (indirectly calculated in per-
ipheral PBMC DNA using the sj/β-TREC ratio, [4]), was
associated with increased risk of death from any cause
(Ferrando-Martinez, Seville, Spain). Multivariate analysis
showed that lower thymic function, higher CRP levels,
and presence of neutrophilia were independently asso-
ciated with time to death in this cohort. Based on these
results the use of the “CRT” index (CRP and Thymic
function) was proposed to define a biomarker profile to
identify individuals at higher risk of death [5]. There
were some limitations to this study regarding the role ofCMV because most of the elderly in Spain are CMV-
seropositive, as in Singapore. We therefore need a more
sophisticated analysis than mere sero-positivity or –
negativity, because it is clear that the way that an indi-
vidual deals with the infection is very important (as illu-
strated in the LLS by Derhovanessian, mentioned above).
This question was approached by Hurme (Tampere,
Finland) who presented results on transcriptomic ana-
lysis of CMV reactivation in seropositive nonagenar-
ians. The presence of CMV DNA was found not to
correlate with T cell subset distribution or with the levels of
inflammatory markers. In the Vitality study, a cohort of
131 nonagenarians, a genome-wide gene expression
array was performed. The results showed that 55 genes
were upregulated and 65 genes downregulated. The
most highly upregulated gene is the H3F3C gene in the
PKA pathway. It is questioned whether the presence of
CMV DNA is due to passive release, rather than due to
an active, productive infection and the possibility of an
inefficient immune elimination.
Is immunosenescence treatable
Cicin-Sain (Braunschweig, Germany) and Nikolich-Zugich
(Tucson, Arizona, USA) analyzed cause-effect relation-
ships between CMV infection and age-associated changes
in the immune system using an experimental murine
model of life-long CMV infection. Several changes consist-
ent with the development of an IRP (e.g. enrichment of ef-
fector memory CD8 cells) were observed in mice infected
with MCMV but not in control mice infected with non-
persistent virus or with other herpesviruses. MCMV infec-
tion resulted in loss of CD8 T-cell functional activity
against other viruses that correlated with the accumula-
tion of MCMV-specific EM cells, suggesting that these
cells may compete with the responses against novel anti-
gens [6,7]. In general, therefore, these results in mice are
similar to those seen in humans. It may therefore be ap-
propriate to use this animal model to investigate the
effects of anti-viral agents on immunosenescence in
the elderly.
To this end, Beswick and Moss (Birmingham, UK) pre-
sented a model using elderly mice with latent CMV in-
fection to analyze whether antiviral therapy can reverse
the development of immune senescence. Administering
valaciclovir antiviral treatment for 12 months signifi-
cantly reduced the frequency of MCMV-specific T-cells
in 18 month-old mice with pre-existing memory infla-
tion and the residual immune response was less highly
differentiated. Furthermore, this treatment lead to a res-
toration of the frequency of naive CD8+ T cells, and
improved the de novo immune response to Influenza
challenge as seen by improved survival and a higher fre-
quency of Influenza- specific lymphocytes in the medias-
tinal lymph nodes. In addition, MCMV infection with
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did not elicit memory inflation and therefore these
investigators concluded that lytic viral reactivation is key
to the accumulating MCMV-specific immune response.
If these results could be translated into clinical practise,
the implications would be very exciting.
Nikolich-Zugich (Tucson, Arizona, USA) also pre-
sented data on CMV infection and T cell ageing in mice
showing that lifelong CMV infection leads to an
increased mortality in aged mice, reduced immune re-
sponse to infections and reduced polyfunctionality of
lymphocytes. In humans, a search for the IRP and the ef-
fect of CMV in a cross-sectional analysis of a mixed US
cohort showed that the absolute loss of naïve cells was
due to ageing as it occurred in both CMV+ and CMV-
individuals, whereas the increase of CD8+ EM cells and
a decrease of the total CD8+ T cell pool were due to
CMV infection. There is some controversy as to the ef-
fect of CMV in this context, because some studies have
shown that a significant age-associated deficit of naïve
CD8+ T cells is not seen in CMV-seronegatives, or at
least not to anything like the same extent. A more
detailed consideration of the impact of CMV on these
parameters is therefore required.
The effect of ageing and CMV on adaptive immunity
A diverse T cell repertoire is required to develop effect-
ive pathogen-specific immunity, and it is therefore im-
portant to assess virus-specific T cells and those
recognizing other pathogens in elderly people. Wang
(Baltimore, Maryland, USA) presented a study on CMV-
specific repertoire diversity and antibody levels in young
and older adults. Using a single-cell strategy for clonoty-
pic analysis of the TCRαβ repertoire of CD8+ T cells,
they analyzed the diversity and magnitude of the CMV-
specific CD8+ T-cell response. It was found that TCRαβ
diversity, but not the size of the T-cell response, was in-
versely related to antibody levels against CMV, which in
turn was associated with the detectability of circulating
viral DNA. These results indicate that the CMV-specific
CD8+ TCRαβ repertoire diversity may be more import-
ant than the size of the CD8+ T cell response in viral
control [8].
A major question remains whether age impacts on the
breadth, frequency and stability of CD4 and CD8 T cell
specificities in healthy donors, and to what extent CMV
is responsible for any such effects? Wills (Cambridge,
UK) tried to answer that question by analyzing the re-
sponse towards multiple CMV antigens. It was found
that IE-1-, pp65-, US3- and pp71-specific CD8+ T cells
are able to control the dissemination of virus in vitro.
The ability of CMV-specific CD8+ T cells to control
virus dissemination was not affected by donor age.
Young, middle aged and old individuals had good CTLresponses and produced IFN-γ. CD4 cells target the la-
tent proteins UL138 and LUNA; a proportion of this re-
sponse is mediated by Th1 cells while other cells
involved in of the response secrete the immunosup-
pressive cytokines IL-10 and TGF-β. These results
emphasize the importance of maintaining effective
immunosurveillance against CMV at any age. This work
challenges the opinion that the immune response to
CMV in the elderly is focused on a small number of pro-
teins and is characterized by lower functionality com-
pared to younger individuals. Kern (Brighton, UK)
presented an analysis of T cell response to 19 different
CMV targets previously identified to be the most rele-
vant CD4 and CD8 T-cell target antigens in the CMV
proteome [9]. Using multi-parameter flow cytometry
and intracellular cytokine staining (ICS) they evaluated
multiple functions and phenotype markers in parallel,
including IL-2, TNF-α, IFN-γ, CD40L, degranulation,
and the memory surface markers, CD45RA and CD27.
No significant age-associated differences with respect to
CD4+ T cell responses were found in their preliminary
data analysis, but there was an apparent increase in the
size of the CD8+ T cell response in older age (manu-
script in preparation). Those individuals with the great-
est single protein-specific responses had retained broad
responses in terms of target recognition. In addition,
there was no apparent reduction of functional breadth,
neither in CD4+ nor CD8+ T-cells. This seems to indi-
cate that responses do not concentrate on fewer specific
target proteins as a consequence of aging. These results
seem to support the notion that neither the quantity nor
the quality of the T cell mediated anti-CMV response is
affected by ageing. Reports published several years ago
seemed to indicate that with respect to very select speci-
ficities, there may be a functional loss [10]. This is likely
owed to differences in technology, where staining of
CD8 T-cell with tetramers detects non-functional cells
that will not be detected using ICS. However, the results
from Kern’s lab clearly show that CMV-specific poly-
functional T-cells do not decrease in absolute numbers
with advancing age, suggesting that non-functional T-
cells might occur in addition to but not in the place of
fully functional T-cells [11]. Riddell and Akbar (London,
UK) analyzed the avidity of CMV-specific CD8 T cells in
the elderly. CMV infection induces the accumulation of
CMV-specific CD45RA+ memory CD8+ T cells. Tetra-
mer binding avidity correlates inversely with CD45RA
expression whereas high TCR avidity is associated with
enhanced effector function (CD107 expression, IFN-γ
and TNF-α production). The functional characterization
of HLA-A*0201-restricted pp65-specific CD8+ T cells
that accumulate with age showed that they had low avid-
ity. The causes of this accumulation and implications for
immunosenescence are open questions.
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its evolution over time after primary infection, or on cell
phenotypes in immune tissues other than blood. Van Lier
(Amsterdam, The Netherlands) presented data on TCR di-
versity in healthy donors and kidney transplant recipients
using high throughput sequencing of CDR 3 regions. The
clonal distribution of CMV-specific clones is relatively
stable. IE-1 responses differ in that they are more
restricted. CMV-specific cells represented a minor fraction
of the CD8+ T cell pool found in the lymph nodes. In con-
trast to peripheral blood, pp65-reactive CD8+ T cells from
lymph nodes resemble central memory-like cells [12]. It is
suggested that CMV-specific clones in lymph nodes can be
recruited into the circulating pool upon CMV reactivation.
Sansoni (Parma, Italy) explored anti-CMV CD8+ T cell
responses in a cohort of CMV- seropositive elderly indivi-
duals. The results indicate that absolute numbers of anti-
CMV CD8+ T cells did not significantly change with age.
Increasing age correlates with the loss of naïve CD8+ T
cells, but not with the expansion of CD28+ memory or
CD28− effector CD8+ T cells. By contrast, the magnitude
of anti-CMV responses is not correlated with naïve CD8+
T cells, but strongly correlates with the accumulation of
antigen-experienced CD8+ T cells. These results suggest
that there is a dichotomy between age and anti-CMV
responses acting as independent factors subverting the
naïve pool and EM cell subset respectively.
The accumulation of large numbers of CD8+ effector
T cells, frequently CMV-specific, may hamper the ef-
fect of vaccination and exacerbate the development of
age-related diseases. Grubeck-Loebenstein (Innsbruck,
Austria) reported that resting CD8+ CD28− effector T
cells, that are more prone to undergo apoptosis follow-
ing DNA damage, can be rescued by cytokines. Thus,
CMV-specific CD8+ CD28− T cells may survive and ac-
cumulate in the bone marrow, specifically in the elderly,
due to high IL-15 and IL-6 production. It is suggested
that in elderly individuals, CD8+ CD28− T cells may
represent a useful line of defence against pathogens such
as CMV and may compensate for the loss of naïve and
early memory T cells. In another set of experiments
aimed at analyzing in vitro the production of cytokines
by fibroblasts in young and elderly individuals it was
observed that CMV infection induced the production of
IL-6 and IL-8, particularly in old age. Thus, lifelong in-
fection with CMV may contribute to age-related inflam-
matory processes, referred to as inflammageing. Clearly,
CMV infection affects many cell types and has wide-
ranging direct and indirect effects also on innate im-
mune mechanisms [13,14].
HCMV infection, ageing and innate immunity
Lopez-Botet (Barcelona, Spain) analyzed NK cell responses
to CMV. CMV- seropositivity is associated with a variableand persistent increase of NKG2Cbright NK cells in
healthy adults and children. NKG2Cbright NK cells do
not co-express NKG2A, display lower levels of NKp30
and NKp46 activating receptors and include higher
numbers of cells bearing LILRB1 and KIR inhibitory
receptors specific for HLA class I molecules. The pro-
portions of NKG2C+ NK cells and the NKG2Cbright
phenotypic profile appeared comparable in HCMV+
individuals of different ages (median: 19, 49 and 70
years). CMV infection has been reported to induce a
marked NKG2Cbright differentiation and expansion in
kidney and stem cell transplantation recipients and in
immunodeficient patients. It is hypothesized that the
interaction of the activating CD94/NKG2C receptor with
a ligand on infected cells, together with cytokine-
mediated signaling (e.g. IL-15), may induce the differen-
tiation and expansion of this NK cell subset.
Several age-related changes in NK cells were reported
by Solana (Córdoba, Spain). In elderly individuals, the
percentage of NK cells is increased. The analysis of NK
cell subsets in the elderly shows an increase of the more
mature CD56dim NK cells and a decrease of CD56bright
NK cells. The expression of CD16 allows the identifica-
tion of a novel CD56−CD16+ subset that is increased in
the elderly. Analysis of activating receptors shows that
NKp30, NKp46 and DNAM-1 are significantly decreased
in the elderly. Decreased per-cell NK cell cytotoxicity
and a decreased capacity of NK to collaborate in DC
maturation (NK-DC crosstalk) are observed in elderly
individuals. The remodeling of NK cell subsets together
with the decreased expression of NCRs and DNAM-1
may contribute to explaining the functional alterations
found in NK cells from the elderly [15,16].
A key component of the innate immune system is
mannose-binding lectin (MBL). Naumova (Sofia, Bulgaria)
studied gene polymorphisms that have been described to
correlate with MBL production capacity [17]. The low se-
cretor haplotypes are very common worldwide, making
MBL-deficiency the most common form of immune defi-
ciency. MBL deficiency is frequently asymptomatic, but
may become symptomatic when associated with other im-
mune system stressors. The relevance of two innate im-
munity gene systems KIR and MBL2 for successful ageing
was discussed. MBL2-deficient haplotypes are associated
with high levels of anti-CMV antibodies in the elderly.
Extrinsic factors affecting immunosenescence: role of CMV?
Bosch (Amsterdam, The Netherlands) analyzed the
effects of CMV on immunity in young adults, and the
role of life style and psychological stress on the immune
response to CMV. The analysis of a cohort of 160 healthy
university students showed that CMV-seropositive indivi-
duals had a reduction in their CD4:CD8 ratio, an increase
of EMRA T cells, elevated plasma IL-6 and lower response
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mentary signs of immune senescence can already be
observed in CMV-infected young adults. In another co-
hort study (Augsburg EADS, 950 factory workers, mostly
males) an association of low income and low education
status with CMV-seropositivity was observed. Moreover,
in CMV-seropositives, the increase of late differentiated
CD8 T cells was positively correlated with lower income
and lower education status.
Rector, (Birmingham, UK), analyzing the same cohort,
found that smokers were 79% more likely to be CMV+.
Other lifestyle factors, such as alcohol consumption and
exercise, were not significant. Cardiovascular risk factors
like triglycerides and several psychological factors such
as sleep disturbances, vital exhaustion, depression, and
self-assessed mental health were positively correlated
with CMV titers. These findings raise the possibility that
the associations between morbidity/mortality and CMV
observed in older adults may be secondary to life style
and socio-economic correlates of CMV infection in
young and middle-aged adults, setting the stage for
poorer health in later life. The analysis of differentiated
EM and EMRA CD8β cells showed that, this population
decreased with increasing age in those that were CMV+,
but not in those that were CMV–.
Clinical implications of latent HCMV infection and
immunosenescence
The impact of measurement errors on the relationship
between CMV infection and clinical outcome was
explored by Wang (Baltimore, Maryland, USA) by a
strategy of data simulation based on data and regression
coefficients from the Women’s Health and Ageing Stud-
ies. The results from this study showed that measure-
ment errors lead to a significant underestimation of the
effect of CMV infection on chronic disease and mortality
risk that should be considered in these studies.
It is well-known that elderly individuals generally have
a worse response to vaccination than the young. Govind
(Cranfield, UK) presented data from the MARKAGE
European Study to establish biomarkers of human age-
ing. In order to identify those individuals who will not
respond effectively to vaccination, the group aims to
identify a set of biomarkers of ageing. Absolute quantifi-
cation of herpes viral load achievable in urine (CMV,
HHV6a and 6b are detectable) may represent a useful
non-invasive diagnostic method for immune competence
in older individuals.
McElhaney (Vancouver, Canada) presented data on
biomarkers of “inflammageing”, the chronic elevation of
inflammatory mediators that weakens the immune sys-
tem as we age. A key role in inflammageing may be
played by chronic CMV infection that stimulates and
thereby exhausts the immune system, as previouslymentioned. In response to influenza vaccination, a high
proportion of potentially senescent CD8+ T cells do not
co-express Granzyme B (GrzB) and Perforin. Using the
baseline level of GrzB, a biomarker called bGrzB has been
developed. The level of bGrzB increases with age and is
higher in CMV+ than in CMV− donors. GrzB is co-
localized with CD8+ T cells in atherosclerotic lesions lead-
ing to plaque instability. In heart failure, GrzB is released
from CD8+ T cells most probably due to the chronic in-
flammatory stimulus associated with this disease.
Frasca (Miami, Florida, USA) assessed activation-
induced cytidine deaminase (AID) as a biomarker of B
cell function. AID is crucial for somatic hypermutation
and class-switch recombination. A reduced serum re-
sponse of the elderly to influenza vaccination assessed
by ELISA and hemagglutination inhibition assays is
commonly observed. In vitro AID responses to CpG
were also decreased with age and correlated with serum
response. The age-associated defects in B cell function
may be due to the increased levels of systemic TNF-α
(which are positively correlated with levels of CMV
IgG), which induce more TNF-α production by B cells
and this pre-activated status of the B cells renders them
refractory to undergo in vitro class switching.
The NHANES III study on nutrition and health in
the USA between 1988 and 1994 was a cross-sectional,
multistage, stratified, clustered probability sample of
the US civilian non-institutionalized population that
included CMV serology. This information was used by
Hill (Portland, Oregon, USA) to test the association
between CMV seropositivity and mortality, using Cox
logistic regression. Consistent with the results of Aiello
mentioned below who had previously analyzed the same
dataset, it was found that CMV produces a modest
increased risk for all-cause mortality. The impact of
CMV was largely explained by an increase in cardiovas-
cular (CVD) deaths. CMV’s main impact was seen in
individuals aged 55–75 at the time of the survey, and par-
ticularly in the 55–65 year age group. CMV imposed little
increased risk of either all-cause or CVD mortality in the
most elderly (aged 75–90). High cholesterol was asso-
ciated with CVD mortality only in the younger age group.
These results may reflect a selective loss from the
population of individuals with the highest risk of CVD
mortality due to unknown or unmeasured factors.
Aiello (Ann Arbor, Michigan, USA) presented data on
CMV, stress and immune markers of ageing. The social
gradient in health may act in part through stress path-
ways. Reactivation of herpesviruses is considered a hall-
mark of psychosocial stress. Using data from NHANES
III, Aiello and colleagues found that those with lower in-
come and education levels were more likely to be CMV
seropositive and have higher IgG antibody titers against
CMV than those with higher income and education [18].
Figure 2 Age and CMV infection are major driving forces contributing to the deterioration of innate and adaptive immunity.
Age-associated decrease of adaptive immunity is termed immunosenescence. The deregulation of innate immunity is associated with
inflammageing. Immunosenescence and inflammageing play a significant role in the pathogenesis of different clinical situations that can lead
to increased risk of frailty and death in the elderly.
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against CMV may reflect increased likelihood of expos-
ure, higher dose of infection and/or poorer immuno-
logical control of CMV. CMV seropositivity as well as
elevated CMV IgG antibody titer have, in turn, been
associated with increased risk for all-cause mortality
[19,20]. Using data on persons 18 years of age and older
from the Detroit Neighborhood Health Study, Aiello
et al. examined the possible immunological mechanisms
which may link CMV to mortality. Elevated CMV IgG
antibody titer was associated with an increased ratio of
late differentiation-stage EMRA T cells to naïve cells
even after controlling for age, medication use and co-
infection with herpes simplex virus-1. Therefore, im-
munological ageing due to elevated immune response
against CMV may be a novel biologic pathway by which
psychosocial stressors impact risk for mortality.
Persistent infection with CMV is thought to be a key
factor for the amplification of the inflammation asso-
ciated with ageing. Maier (Leiden, The Netherlands) pre-
sented an analysis of the innate immune capacity,
measured by LPS induced cytokine production capacity
of whole blood, and CMV infection in three different
cohorts, the Leiden Longevity Study, Prosper Study and
Leiden 85-Plus Study. However, levels of proinflamma-
tory and anti-inflammatory cytokines produced upon
LPS stimulation showed no correlation with CMV seros-
tatus or with CMV IgG levels in these three cohorts.
However, cytokine production capacity from CMV– orCMV+ donors showed high interindividual variability
and reflected survival propensities and metabolic disease.
Analyses on comorbidities and CMV infection showed
higher prevalence of diabetes, higher non-fasting glucose
levels and glycosylated haemoglobin (HbA1c) in CMV+
oldest old participants, but there was no correlation with
CMV IgG titers [21].
The possible relationship between diabetes mellitus
(DM) Type 2, elderly, frailty and CMV have been analyzed
by Fülop (Sherbrooke, Canada). CMV-seropositivity is
more prevalent in diabetic elderly subjects. It seems that
chronic disease is a more important determinant for frailty
than the CMV status. CMV+ elderly DM patients have
less putatively senescent cells than healthy CMV-
seropositives but express more CD57 at the single cell
level which is more accentuated in CD8+ T cells. After in-
fluenza vaccination, the highest level of GrzB is found in
CMV− DM patients that had the lowest level of poten-
tially senescent cells. Diabetes seems to suppress the per-
centage of these CD8+ T cells.
The possibility that infection by CMV or other herpes-
viruses could be related to inflammatory diseases has
been explored by Sauce (Paris, France) who analyzed the
capacity to respond to CMV and EBV by Systemic Lupus
Erythematosus (SLE) active and inactive patients. A dis-
crepancy between CMV and EBV response was observed
in SLE patients. Whereas CMV responsiveness was not
altered, the response to EBV was depressed, with lower
IFN-γ, TNF-α, MIP1β and IL-2 secretion and lower
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exhausted T cell phenotype (PD-1hi) since PD-1 blocking
restores responsiveness [22].
CMV is still regarded as being the most significant in-
fectious pathogen in the solid organ transplant recipient,
and in spite of the improvements in surveillance and
treatment, it continues to be a major cause of morbidity
and mortality after transplantation and is associated with
lower graft survival. Appay (Paris, France) focused on
the role of CMV in the pathogenesis of acute rejection
in lung transplantation. An association between cellular
immune activation (i.e. expression of CD38 on T cells)
and acute rejection was found. Levels of total CD38+
CD8+ T cells correlated with the frequency of CMV-
specific cells. The development of pro-inflammatory
CMV-specific CD8+ T cell immune responses may ex-
plain the relationship between CMV infection and acute
lung rejection. It is suggested that potent CMV prophy-
laxis should be given to all CMV-seropositive patients to
prevent the occurrence of acute rejection. CD8+ T cell
activation levels in peripheral blood correlate well with
CD8 responses in the lung and may predict the risk of
acute rejection. Zielinski (Gdansk, Poland) analyzed CMV
infection in renal transplantation patients. In a retrospect-
ive study, it was observed that elderly kidney recipients,
CMV-positive with high numbers of CD28− T cells and
short telomeres, had fewer episodes of acute rejection.
Preliminary data suggest that CMV challenge has a strong
impact on the immune system after allotransplantation
in the elderly. Solana and Cantisan (Cordoba, Spain)
reported an analysis of CD45RA+ (EMRA) CMV-specific
CD8 T cells in relation to CMV replication parameters in
solid organ transplantation. It was observed that EMRA
increase by 4% for each log of viral replication. Replication
is associated with continuous and constant increases in
percentages of CD28− cells. The impact of CMV on indu-
cing expansion of CD28− CMV-specific CD8 T cells is
seen mainly in young individuals [23].
Future directions and concluding remarks
Significant advances in the understanding of the changes
of immune system associated with CMV infection and
their possible significance for immunosenescence have
been made over the past few years in many areas of
medicine, as reported here.
In this workshop, many important questions have been
addressed and other new questions been raised. A panel of
markers to assess T cell phenotypes in T cells subsets in
studies of immunosenescence and CMV infection was pro-
posed and discussed, as well as the significance of the IRP
phenotype, markers of thymic function or inflammation
on survival in the elderly. The role of CMV in im-
munosenescence has been confirmed in experimental mod-
els, opening new perspectives to explore possible therapiesaimed at reversing immunosenescence. However, a major
question still remains concerning the mechanisms driving
the homeostatic fluctuations of CD8 T cells during latency
of CMV infection, and how age impacts on the breadth,
frequency, phenotype and function of CD4 and CD8 T cell
specificities in healthy donors. Although primarily affecting
the T cell compartment, evidence is accumulating in sup-
port of a significant effect of CMV infection and ageing on
innate immunity as well, in particular NK cells.
Results from translational research of CMV infection
and immunosenescence in clinical conditions such as
transplantation, cancer, immunodeficiency and auto-
immune and inflammatory diseases, supports the notion
that CMV can affect their evolution and prognosis by in-
ducing a process of “early” immunosenescence (Figure 2).
Furthermore, other extrinsic factors can also contribute,
together with CMV, to the age-associated deterioration
of the immune system.
However, there are still many open questions about the
immune response to HCMV itself in ageing and about the
role of CMV in early immunosenescence (Figure 1):
a) It is likely that humans can be infected with multiple
CMV strains. How does this affect their interactions
within the immune system and their effect on
immunosenescence?
b) What is the real impact of the complexity of CMV
infections on the processes of T cell homeostasis and
differentiation in the course of ageing?
c) It is necessary to test the function of T cells in ageing
and CMV infection before they are labeled as
“senescent”, “exhausted” or in other manner inadequate.
d)What is the contribution of CMV- induced
inflammation to inflammageing? What are the best
markers that could be used to define CMV-induced
systemic inflammation?
It was proposed that the organization of a 4th work-
shop is vital for the field to move forwards, to answer
these and other questions. We are grateful to Paolo
Sansoni who agreed to organize it in Parma (Italy) in 2013.
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